

# Clinical Management of COVID-19 in Healthcare Setting

## Second Edition

### Prepared by:



Government of Nepal  
Ministry of Health and Population  
Department of Health Services  
Epidemiology and Disease Control Division

## TABLE OF CONTENTS

ACKNOWLEDGMENT	IV
INTRODUCTION TO THE SECOND EDITION	1
PURPOSE OF THE POCKET BOOK	2
TARGET GROUPS	2
1. COVID-19 OVERVIEW	2
2. SCREENING AND TRIAGE	4
Table 1. Case Definitions	7
1. FLOW CHART: TRIAGE AND ISOLATION	9
3. THE COVID-19 CARE PATHWAY	10
3.1 Discontinue transmission-based precautions	11
4. DISEASE SEVERITY	12
Table 2. Clinical Symptoms of COVID-19 and Risk Factor	13
5. MANAGEMENT OF COVID-19 CASES ACCORDING TO DISEASE SEVERITY	15
5.1 Case Management of MILD COVID-19 cases	16
5.1.1 Case Management of MODERATE COVID-19 cases	17
5.1.2 Case Management of SEVERE COVID-19 cases	18
5.1.3 Case Management of CRITICAL COVID-19	19
5.1.4 ARDS protocol and PEEP titration	20
Algorithm 5: Management of Critical COVID-19 Sepsis and Septic Shock	21
6. PRONE POSITIONING	23
6.1.1 Prone positioning in intubated severe COVID-19 patients	23

6.1.2 Awake prone positioning in moderate to severe disease	23
Algorithm 6. Treatment for Children with septic shock	25
Algorithm 7. Delivering increasing oxygen in ADULT	27
Algorithm 8: Delivering increasing oxygen in CHILDREN	28
7. THERAPEUTICS FOR COVID-19	32
7.1 CORTICOSTEROID THERAPY AND COVID-19	32
7.2 Remdesivir	33
7.3 Tocilizumab	33
8. TREATMENT OF OTHER ACUTE AND CHRONIC INFECTIONS IN PATIENTS WITH COVID-19	35
8.1 Use of antimicrobials	35
8.2 Chronic infections	36
8.3 Endemic diseases	36
9 USE OF OSELTAMIVIR	36
10 USE OF VASOPRESSORS	37
11 USE OF INOTROPES	37
12 NON-COMMUNICABLE DISEASES (NCD) and COVID-19	37
12.1 Antihypertensive patients	37
12.2 Asthmatic patients	38
12.3 Diabetic patients	38
12.4 Patients with myocarditis	38
13 PREVENTION OF COMPLICATIONS IN HOSPITALIZED AND CRITICALLY ILL PATIENTS WITH COVID-19	38
13.1 Thromboembolism	38

13.2	Other complications	39
13.3	Nutrition	39
14	MANAGEMENT OF PREGNANT AND LACTATING WOMEN AND COVID-19	39
15	MANAGEMENT OF NEUROLOGICAL AND MENTAL MANIFESTATIONS ASSOCIATED WITH COVID-19	42
16	Rehabilitation of COVID-19 Patients	43
	ANNEX 1: APPROPRIATE USE OF PPE ACCORDING TO TASK	45
	ANNEX 2. SCREENING QUESTIONAIRRE	47
	ANNEX 3. EDUCATION FOR PATIENTS; HOW TO PERFORM HAND HYGIENE, COUGH ETTIQUETTE, WEAR A MASK PROPERLY	48
	ANNEX 4: DIFFERENTIAL DIAGNOSIS MATRIX	52
	ANNEX 5: NATIONAL EARLY WARNING SCORE 2	53
	ANNEX 6: MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN AND ADOLESCENTS	57



## ACKNOWLEDGMENT

The Director General, Dr. Dipendra Raman Singh, Department of Health Services, Ministry of Health and Population, Nepal expresses sincere gratitude to all the authors and reviewers of **“Pocket Book of Clinical Management of COVID 19 in Healthcare Setting: Second Edition”** particularly to World Health Organization, Nepal and all others who contributed to this concise yet comprehensive book.

### List of Contributors

1. Dr. Roshan Pokharel, Chief Specialist, MoHP
2. Dr. Guna Raj Lohani, Division Chief, MoHP
3. Dr. Krishna Prasad Paudel, Director, EDCCD
4. Dr. Amrit Pokhrel, EDCCD
5. Dr. Sagar Raj Bhandari, Director, STIDH
6. Dr. Anup Banstola, STIDH
7. Dr. Nisha Jyoti Shrestha, Kanti Children Hospital
8. Dr. Samir Kumar Adhikari, Chief, HEOC
9. Dr. Guna Nidhi Sharma, Sr. Health Administration, MoHP
10. Dr. Santa Das, TUTH
11. Dr. Ashish Shrestha, PAHS
12. Dr. Achyut Karki, Bir Hospital
13. Dr. Prabin Nepal, APF
14. Dr. Rajan Pandey, Bheri Hospital
15. Dr. Sher Bahadur Kumar, Seti Hospital
16. Dr. Reuben Samuel, WHO
17. Prof. Dr. Arunkumar Govindakarnavar, WHO
18. Ms. Shirley McQueen Patterson, WHO
19. Prof. Dr. Shital Adhikari, WHO
20. Dr. Subash Neupane, WHO
21. Dr. Ela Singh Rathaur, SSBH/ USAID

## INTRODUCTION TO THE SECOND EDITION

This is the second edition of the Ministry of Health and Populations, Pocket book for Case Management of COVID-19 in the Healthcare Setting.

The first edition was adapted from the Interim Guidance for Caring of Patients with COVID-19 in Healthcare settings, Nepal Medical Council (NMC) and aligned with Clinical management of COVID-19, Interim Guidance, WHO (May 27, 2020).

The rationale for this updated edition has been to expand the scope of the earlier guidance, bringing together recently updated recommendations from NMCs October 2020 update and COVID-19 Clinical Management: Living Guidance (January 25, 2021) as well as the Clinical Care for Severe Acute Respiratory Infection: Toolkit-COVID-19 Adaptation: WHO 2020 and advice from subject matter experts.

This edition provides updated technical guidance in several case management clinical areas as follows:

- Revision of the release from the COVID-19 clinical pathway criteria
- Addition of Treatment of acute co-infections
- Addition of prevention of complications, immunomodulators and other adjunct therapies
- Revision of recommendations on use of antivirals and corticosteroids in COVID-19
- Assessment of severity by National early Warning Score 2 (NEWS 2)

## PURPOSE OF THE POCKET BOOK:

The purpose of this pocketbook is to help physicians, and healthcare workers, to properly manage persons with suspected or confirmed COVID-19 and to standardize case management of COVID-19 cases throughout the country. It is not meant to replace clinical judgement or specialist consultation, but rather to strengthen frontline clinical management.

## TARGET GROUPS:

The intended target audience are physicians, nurses, other healthcare personnel, involved in the clinical management of COVID-19 cases.

### 1. COVID-19 OVERVIEW<sup>12</sup>:

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-stranded RNA virus that was first recognized in Wuhan, Hubei province, China, in December 2019.

Epidemiology and virologic studies suggest that transmission mainly occurs by close contact through respiratory droplets or by direct contact with infected persons, or by contact with contaminated objects or surfaces, or by aerosols from both symptomatic and asymptomatic people. Clinical and virologic studies have found that shedding of SARS-CoV-2 is highest in the upper respiratory tract (URT) (nose and throat) early in the course of the disease, within the first 3 days from onset of symptoms. The incubation period for COVID-19 is 5-7 days but can be up to 14 days. Some infected persons can be contagious, from 1–3 days before symptom onset (presymptomatic period).

An asymptomatic case is a person infected with SARS-CoV-2 who does not develop symptoms.

Among symptomatic patients, the duration of infectious virus shedding has been estimated at 8 days from the onset of any

---

<sup>1</sup> COVID-19 Clinical Management, Living Guidance 25 January 2021

<sup>2</sup> Clinical management of COVID-19 Interim Guidance: May 2020:WHO

symptoms. About 17% (14-20%) patients will be asymptomatic throughout their illness. A living systematic review (4 studies, 462051 women) found that pregnant and recently pregnant women with COVID-19 appear to be less likely to be symptomatic or manifest common symptoms such as fever, dyspnoea and myalgia, compared with nonpregnant women of reproductive age.

Case definition including common symptoms are given in table 1.

Older age, smoking and underlying noncommunicable diseases (NCDs), such as diabetes, hypertension, cardiac disease, chronic lung disease and cancer have been reported as risk factors for severe COVID-19 disease and death. However, most patient with COVID-19 develop only mild (40%) or moderate (40%) disease approximately 15% develop severe disease that requires oxygen support, and 5% have critical disease with complications such as respiratory failure, acute respiratory distress syndrome (ARDS), sepsis and septic shock, thromboembolism, and/or multiorgan failure, including acute kidney injury and cardiac injury. (Table 2)

COVID-19 is also associated with mental and neurological manifestations, including delirium or encephalopathy, agitation, stroke, meningoencephalitis, impaired sense of smell or taste anxiety, depression and sleep problems. In many cases, neurological manifestations have been reported even without respiratory symptoms. Anxiety and depression appear to be common amongst patient hospitalized for COVID-19.

There are few data on the clinical presentation of COVID-19 in specific populations, such as children and pregnant women. Clinical manifestations of COVID-19 are generally mild in children compared with adults. However, most recently, an acute presentation with a hyperinflammatory syndrome leading to multiorgan failure and shock has been described, as '*multisystem inflammatory syndrome temporally associated with COVID-19 in children an adolescents*'

While most people with COVID-19 recover and return to normal health, some people can have symptoms that last for weeks or even months after recovery from acute illness named post

COVID condition. Even people who are not hospitalized or have mild symptoms can experience persistent or late symptoms.

## 2. SCREENING AND TRIAGE<sup>1,2</sup>:

Screen all persons at the first point of care (POC) at the health facility e.g., OPD, emergency, triage area etc. Ensure IPC precautions are implemented when performing screening of persons (Annex 1). Follow the screening process as follows;

**1. Screening questionnaire:** Screen all persons presenting to the facility by using the simple screening questionnaire (Annex 2)

**2. Temperature checks:** All persons presenting to the facility should have their temperatures taken and recorded

- ! Preferably use a non-touch technique (e.g. infra-red thermometer)

- ! In the absence of a non-touch thermometer, clean the thermometers with 70% alcohol wipe after each use.

- ! Temperatures > 100.4°F or 38° C is considered as fever

**3. Co-morbidities:** Febrile patients should be tested according to facility protocol, irrespective of the presence of respiratory signs and symptoms; screen for high risk of severe COVID-19 disease with priority. Consider other causes of illness (Annex 4 Differential Diagnosis Matrix)

**4. Diagnosis:** After screening, diagnose the patient according to the EDCCD case definitions for COVID-19 (Table 1)

**a.** All suspect cases should be tested to determine if they are a confirmed case. Until proven negative, all suspected cases should remain in the COVID-19 care pathway.

**b.** Laboratory diagnostic testing:

- I. Collection of upper respiratory tract (URT) specimens (nasopharyngeal and oropharyngeal) for testing by RT-PCR (consider using SARS-CoV-2 Antigen RDT when there is no access to RT-PCR) and, where clinical suspicion remains

and URT specimens are negative, collect specimens from the lower respiratory tract (LRT) when readily available (expectorated sputum, or endotracheal aspirate/ bronchoalveolar lavage in ventilated patient).

- II. In addition, testing for other respiratory viruses and bacteria should be considered when clinically indicated.
- III. If testing not available, the person becomes a probable case based on clinical suspicions and should be managed for in the COVID-19 pathway.

Consider, and test for other endemic diseases when clinically indicated e.g.:

Malaria  
Dengue,  
Scrub Typhus,  
TB etc.

Co-infections / morbidity with COVID-19 may be present

Recognize high risk groups for severe COVID-19 disease (Table 1.)

**5. COVID-19 Pregnant and post-partum women:** with pre-existing or pregnancy related co-morbidities (e.g., pregnancy induced hypertension, gestational diabetes, should also be considered for close monitoring

**6. Isolation:** All suspected or confirmed COVID-19 cases, with or without co-morbidities should be given a medical mask to wear and entered into the COVID-19 pathway

**7. Documentation:** All information gathered during the screening process, should be documented and recorded on individual patient forms.

## PROTECT YOURSELF AND OTHERS

- Follow IPC measures at all times
- Wear PPE according to the activity risk
- Always follow & perform 5 moments of hand hygiene
- Maintain physical distancing of > 2 meters

# Table 1. Case Definitions

Updated in Public health surveillance for COVID-19, published 7 August 2020

## Suspect COVID-19 case

A person who meets the clinical AND epidemiological criteria:

### Clinical Criteria:

- Acute onset of fever AND cough;
- OR
- Acute onset of **ANY THREE OR MORE** of the following signs or symptoms:
  - fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anorexia/nausea/vomiting, diarrhoea, altered mental status

### AND

### Epidemiological Criteria:

- Residing or working in an area with high risk of transmission of virus: closed residential settings, humanitarian settings such as camp and camp-like settings for displaced persons; anytime within 14 days prior to symptom onset;
- OR
- Residing or travel to an area with community transmission anytime within the 14 days prior to symptom onset;
- OR
- Working in any health care setting, including within health facilities or within the community, anytime within the 14 days prior to symptom onset.

A patient with **severe acute respiratory illness**: (SARI: acute respiratory infection with history of fever or measured fever of  $\geq 38^{\circ}\text{C}$ ; and cough; with onset within the last 10 days; and requires hospitalization).

## Probable COVID-19 case

A patient who meets clinical criteria above AND is a contact of a probable or confirmed case, or epidemiologically linked to a cluster with at least one confirmed case

A suspect case with chest imaging showing findings suggestive of COVID-19 disease\*

\*Typical chest imaging findings suggestive of COVID-19 include the following:

- **Chest radiography:** hazy opacities, often rounded in morphology, with peripheral and lower lung distribution.
- **Chest CT:** multiple bilateral ground glass opacities, often rounded in morphology, with peripheral and lower lung distribution.
- **Lung ultrasound:** thickened pleural lines, B lines (intercostal fascies), or confluent consolidative patterns with or without air bronchograms.

A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in the absence of any other identified cause.

Death, not otherwise explained, in an adult with respiratory distress preceding death AND was a contact of a probable or confirmed case or epidemiological linked to a COVID-19 cluster with atleast one confirmed case.

## Confirmed COVID-19 case

A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.

See: Laboratory testing for coronavirus disease (COVID-19) in suspected human cases guidance. For details

### NOTE:

Clinical and public health judgment should be used to determine the need for further investigation in patients who do not strictly meet the clinical or epidemiological criteria. Surveillance case definitions should not be used as the sole basis for guiding clinical management.



## **SARS-CoV-2- Variant of Interest (VOI)**

A SARS-CoV-2 isolate that is phenotypically changed compared to a reference isolate or that has a genome with mutations that lead to amino acid changes associated with established or suspected phenotypic implications; AND has been identified to cause community transmission/multiple COVID-19 case clusters, or has been detected in multiple countries.

**OR**

is otherwise assessed to be a VOI by WHO in consultation with the WHO SARS-CoV-2 Virus Evolution Working Group (VEWG).

## **SARS-CoV-2 Variant of concern (VOC):**

A VOI (as defined above) that, through a comparative assessment, has been demonstrated to be associated with:

- Increase in transmissibility or change in the epidemiology.
- Increase in virulence or change in disease presentation; or
- Decrease in effectiveness of available diagnostics, vaccines, therapeutics, or public health and social measures.

# 1. FLOW CHART: TRIAGE AND ISOLATION

Does the person have any of (new-onset) fever, cough, shortness of breath, chills, muscle pain, acute loss of taste or smell, diarrhea or sore throat in the last 14 days?

No

Yes

History of contact with a confirmed or probable COVID-19 case in the last 14 days prior to symptom onset?

No

COVID-19 less likely

Yes

COVID-19 Suspect

No

Alternative explanation/diagnosis to the person's symptoms/signs?

Yes

COVID-19 less likely

Asymptomatic/Pre-symptomatic/Mild COVID-19 Infection

Moderate / Severe /Critical COVID-19 Infection

Pneumonia, ARDS, Sepsis, Shock

Hemodynamically stable  
SpO<sub>2</sub> > 93% in room air  
No respiratory distress

Admit to ISOLATION/COVID WARD

- SpO<sub>2</sub> ≤ 93% in room air at rest
- RR ≤ 30 breaths/min
- SpO<sub>2</sub> ≤ 94% on ≤ 4 L/min O<sub>2</sub>
- Hemodynamically stable
- High risk for severe disease\*\*

Isolate

Test -ve

Test +ve

Repeat test if suspicion high  
Management of alternative diagnosis

- Repeat sampling if strong clinical suspicion
- Manage alternative diagnosis

- Monitor clinical status for worsening.
- SpO<sub>2</sub> and temperature monitoring every 6 hourly
- Clinical evaluation if SpO<sub>2</sub> drops by >2%
- Admission in COVID ward if high-risk for severe disease\*\*
- Contact and droplet precautions
- Symptomatic and psychosocial support
- Ambulation when awake to reduce the risk of VTE

\*\*High risk for severe disease

- Age > 60 yrs
- Cardiovascular disease including HTN
- DM & other immune compromised conditions
- Chronic lung/kidney/liver/CNS diseases
- Obesity

Discharge Criteria

Symptomatic patient

10 days after symptoms onset plus 3 days without symptoms (without fever and respiratory symptoms)

Asymptomatic patient

10 days after test is positive

- Ambulation/Pharmacologic DVT prophylaxis if no contraindications.
- Supplemental O<sub>2</sub>/HFNC\*/NIV\* (aerosolization risk\*)
- Awake proning >12-16 hours a day if able to communicate
- Dry nebulization (salbutamol MDI 4puffs with spacer) SOS
- Intubate if: i) worsening distress ii) failure to maintain SpO<sub>2</sub> ≤ 90% @15 lit O<sub>2</sub> via NRB or NIV/HFNC iii) PaO<sub>2</sub>/FIO<sub>2</sub> <150
- Antibiotics if sepsis/bacterial pneumonia suspected
- Steroids for severe cases (dexamethasone/prednisone/methylprednisolone X7-10d)
- Restrictive fluid strategy
- Ventilator management as per the ARDSnet protocol
- Use closed suction catheters & viral/HEPA filters in circuits
- Consider proning/paralyzing agents early if PaO<sub>2</sub>/FIO<sub>2</sub> <150
- Nutritional and psychological support

### 3. THE COVID-19 CARE PATHWAY

The patient enters the COVID-19 Care Pathway and follows the continuum of care until they are released from the pathway. All persons enter the COVID-19 pathway after s/he is screened based on a standardized case definition and meets criteria for suspected case.

- ✓ Suspected cases are persons under investigation and should be given and asked to wear a medical mask, and immediately isolated (single isolation rooms preferred) to contain the virus
  - If single isolation rooms are not available, groups the patients with similar diagnosis based on epidemiological risk factors with physical distancing of more than 2 meters apart
- ✓ Suspected cases should not be cohorted with confirmed cases
- ✓ Probable cases are persons for whom testing for COVID-19 (SARS-CoV-2) is inconclusive or not available but clinical suspicion remains high
- ✓ Confirmed cases are persons with laboratory confirmation of COVID-19
- ✓ Consideration for co-infections and/or chronic diseases must be made within the COVID-19 pathway

COVID-19 care pathways should be coordinated and multidisciplinary to ensure the delivery of safe and quality care in all levels of the health services.

Clinical monitoring of a COVID-19 patients can be done with National Early Warning Score (NEWS) 2. (Annex 5)

## Routine tests in moderate, severe and critical COVID-19 disease

1. Complete blood count
2. Urea, creatinine, sodium and potassium
3. Liver function tests
4. Where available- CRP, D-dimer, troponin, ferritin, procalcitonin etc.
5. Chest X-ray should be done in all hospitalized patients with fever, cough and shortness of breath. Common findings are patchy infiltrates in multiple areas.

### 3.1 Discontinue transmission-based precautions

(including isolation) and release from the COVID-19 care pathway as follows<sup>3</sup>:

- ✓ **For symptomatic patients:** 10 days after symptom onset, plus at least 3 days without symptoms (without fever, and respiratory symptoms)
- ✓ **For asymptomatic patients:** 10 days after testing positive for SARS-CoV-2
  - ! **Release from the COVID-19 pathway is NOT** the same as clinical discharge from a facility or from one ward to another, e.g. some patients may require ongoing rehabilitation, or other aspects of care, beyond release for the COVID-19 pathway, based on clinical needs in the COVID-19 pathway
  - ! **If discharge from the COVID-19 pathway** consider ongoing rehabilitation, medication reconciliation, plan for follow up with clinical provider in place, routine immunization etc.

---

<sup>3</sup>Criteria for releasing COVID-19 patients from isolation: Scientific Brief 17 June 2020: WHO

## 4. DISEASE SEVERITY<sup>1,2</sup>

The COVID-19 disease is classified into following categories according to severity:

- **Mild disease**-See section 6.1; Algorithm 1
- **Moderate disease**- See section 6.2; Algorithm 2
- **Severe disease**-See section 6.3; Algorithm 3
- **Critical disease**-See sections 6.4, 6.5; Algorithms 4 & 5
  - ARDS
  - Sepsis
  - Septic shock
  - Or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy

See Annex 5 for National Early Warning Score 2 to facilitate monitoring of the patient

**Table 2. Clinical Symptoms Associated with COVID-19 and Risk Factors<sup>2</sup>**

<p><b>Clinical Presentation</b></p>	<p>he spectrum of illness ranges from asymptomatic infection to acute respiratory distress, multiorgan dysfunction. About 40% of patients will be asymptomatic. Presenting signs and symptoms of COVID-19 vary</p> <p>Most persons experience fever (83–99%) though may be absent in close to half of patients initially, cough (59–82%), fatigue (44–70%), anorexia (40–84%), shortness of breath (31–40%), myalgias (11–35%). Other <b>non-specific symptoms</b>, such as sore throat, nasal congestion, headache, diarrhoea, nausea and vomiting, have also been reported . Loss of smell (anosmia) or loss of taste (ageusia) preceding the onset of respiratory symptoms has also been reported</p> <p><b>Older people and immunosuppressed patients</b> in particular may present with atypical symptoms such as fatigue, reduced alertness, reduced mobility, diarrhoea, loss of appetite, delirium, and fever may be absent</p> <p>Symptoms such as dyspnoea, fever, GI symptoms or fatigue due to physiologic adaptations in <b>pregnant women</b>, adverse pregnancy events, or other diseases such as malaria, may overlap with symptoms of COVID-19.</p> <p>Compared with adults, <b>children</b> are less likely to present with fever, cough and shortness of breath</p>
-------------------------------------	--

<b>Risk factors for severe disease</b>	<p>Age more than 60 years (increasing with age)</p> <p>Underlying noncommunicable diseases (NCDs): hypertension, cardiac disease, chronic lung disease, cerebrovascular disease, diabetes mellitus (DM), immunocompromising conditions, and cancer have been associated with higher mortality.</p> <p>Smoking</p>
--	---

## 5. MANAGEMENT OF COVID-19 CASES ACCORDING TO DISEASE SEVERITY


First, protect yourself and others by implementing appropriate IPC measures at all times:

- ! Instruct the patient to wear a medical mask
- ! Maintain physical distancing of 2 meters where possible
- ! Instruct patients to adopt; good hand hygiene, respiratory hygiene, and cough etiquette (Annex 3)
- ! Depending on the activity risk:
- ! Apply standard precautions
- ! Apply contact and droplet precautions
- ! Apply airborne precautions



# 5.1 Case Management of Mild COVID-19 cases


5.1 Case Management of MILD COVID-19 cases  
Algorithm 1: Management of Mild COVID-19 disease



# 5.1.1 Case Management of MODERATE COVID-19 cases

## 5.1.1 Case Management of MODERATE COVID-19 cases


### Algorithm 2. Management of Moderate COVID-19 disease



# 5.1.2 Case Management of SEVERE COVID-19 cases


## 5.1.2 Case Management of SEVERE COVID-19 cases

Algorithm 3. Management of Severe COVID-19 disease:



## 5.1.3 Case Management of CRITICAL COVID-19

Algorithm 4. Acute Respiratory Distress Syndrome (ARDS)



## 5.1.4 ARDS protocol and PEEP titration



NIH NHLBI ARDS Clinical Network  
Mechanical Ventilation Protocol Summary

**OXYGENATION GOAL:  $\text{PaO}_2$  55-80 mmHg or  $\text{SpO}_2$  88-95%**  
Use a minimum PEEP of 5 cm  $\text{H}_2\text{O}$ . Consider use of incremental  $\text{FIO}_2/\text{PEEP}$  combinations such as shown below (not required) to achieve goal.

**Lower PEEP/ higher  $\text{FIO}_2$**

$\text{FIO}_2$	0.3	0.4	0.4	0.5	0.5	0.6	0.7	0.7
PEEP	5	5	8	8	10	10	10	12

$\text{FIO}_2$	0.7	0.8	0.9	0.9	0.9	1.0
PEEP	14	14	14	16	18	18-24

**Higher PEEP/ lower  $\text{FIO}_2$**

$\text{FIO}_2$	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5
PEEP	5	8	10	12	14	14	16	16

$\text{FIO}_2$	0.5	0.5-0.8	0.8	0.9	1.0	1.0
PEEP	18	20	22	22	22	24

**PLATEAU PRESSURE GOAL:  $\leq 30$  cm  $\text{H}_2\text{O}$**

Check Pplat (0.5 second inspiratory pause), at least q 4h and after each change in PEEP or  $\text{V}_T$ .

If Pplat > 30 cm  $\text{H}_2\text{O}$ : decrease  $\text{V}_T$  by 1 ml/kg steps (minimum = 4 ml/kg).

If Pplat < 25 cm  $\text{H}_2\text{O}$  and  $\text{V}_T < 6$  ml/kg, increase  $\text{V}_T$  by 1 ml/kg until Pplat > 25 cm  $\text{H}_2\text{O}$  or  $\text{V}_T = 6$  ml/kg.

If Pplat < 30 and breath stacking or dys-synchrony occurs: may increase  $\text{V}_T$  in 1ml/kg increments to 7 or 8 ml/kg if Pplat remains  $\leq 30$  cm  $\text{H}_2\text{O}$ .

### INCLUSION CRITERIA: Acute onset of


- $\text{PaO}_2/\text{FIO}_2 \leq 300$  (corrected for altitude)
- Bilateral (patchy, diffuse, or homogeneous) infiltrates consistent with pulmonary edema
- No clinical evidence of left atrial hypertension

### PART I: VENTILATOR SETUP AND ADJUSTMENT

- Calculate predicted body weight (PBW)  
Males =  $50 + 2.3$  [height (inches) - 60]  
Females =  $45.5 + 2.3$  [height (inches) - 60]  
Select any ventilator mode
- Set ventilator settings to achieve initial  $\text{V}_T = 8$  ml/kg PBW
- Reduce  $\text{V}_T$  by 1 ml/kg at intervals  $\leq 2$  hours until  $\text{V}_T = 6$  ml/kg PBW.
- Set initial rate to approximate baseline minute ventilation (not > 35 bpm).
- Adjust  $\text{V}_T$  and RR to achieve pH and plateau pressure goals below.

Source: ards.net

## Management of Critical COVID-19 Sepsis and Septic Shock



## **Recommended resuscitation strategies for adult and pediatric patients with septic shock<sup>1</sup>**

- In resuscitation for septic shock in adults, give 250–500 mL crystalloid fluid (Normal saline or Ringer lactate) as rapid bolus in first 15–30 minutes and for septic shock in children, give 10–20 mL/kg crystalloid fluid as a bolus in the first 30–60 minutes. Fluid resuscitation may lead to volume overload, including respiratory failure, particularly with ARDS.
- If there is no response to fluid loading or signs of volume overload appear (e.g. jugular venous distension, crackles on lung auscultation, pulmonary oedema on imaging, or hepatomegaly), then reduce or discontinue fluid administration.
- Determine the need for additional fluid boluses (250–500 mL in adults; 10–20 mL/kg in children) based on clinical response and improvement of perfusion targets and reassess for signs of fluid overload after each bolus.
- Perfusion targets include MAP (> 65 mmHg or age-appropriate targets in children), urine output (> 0.5 mL/kg/hr in adults; 1 mL/kg/hr in children), and improvement of skin mottling and extremity perfusion, capillary refill, heart rate, level of consciousness, and lactate.
- Consider dynamic indices of volume responsiveness: passive leg raises, fluid challenges with serial stroke volume measurements, or variations in systolic pressure, pulse pressure etc. to guide volume administration beyond initial resuscitation based on local resources and experience.

## 6. PRONE POSITIONING

### 6.1.1 Prone positioning in intubated severe COVID-19 patients<sup>5-7</sup>

Early prone positioning for 16-18 hours should be considered in COVID-19 patients with ARDS when  $\text{PaO}_2/\text{FiO}_2$  is  $<150$  mmHg on  $\text{FiO}_2 >0.6$  and  $\text{PEEP} >10$  cm H<sub>2</sub>O). It helps to reduce ventilation perfusion mismatching, hypoxemia and shunting. It requires expertise and patient need to be monitored closely for possible complications- accidental extubation, tube dislodgement, worsening of hemodynamics and hypoxemia. Spinal injury, open chest wound, and 3<sup>rd</sup> trimester of pregnancy are contraindications of prone positioning.

### 6.1.2 Awake prone positioning in moderate to severe disease

UK Intensive care society advocates awake prone positioning to become standard of care for suspected or confirmed COVID-19 in patients requiring oxygen supplementation  $>28\%$ . This will lead to better ventilation perfusion matching believed due to more homogenous lung aeration and strain distribution with recruitment of dorsal lung. Awake prone positioning appears to be safe and may slow or avoid the respiratory deterioration in COVID-19 patients requiring oxygen supplementation. The optimal frequency and duration of awake prone positioning in non-intubated patient is not known. Patients are required to adopt the prone position for 1 hour each, five sessions per day during waking hours.



**PHOTOS BELOW TO DEMONSTRATE THIS**

1. 30 minutes-2 hours: lying on your belly

१. ३० मिनेट देखि २ घन्टा: घोप्टो परेर सुत्ने वा घोप्टो परेर कुहनी, घुँडा र टाउकोले टेक्ने बस्ने



4. 30 minutes-2 hours: lying on your left side

४. ३० मिनेट देखि २ घन्टा: देखे कोल्तो फर्कने



2. 30 minutes-2 hours: lying on your right side

२. ३० मिनेट देखि २ घन्टा: दाहिने कोल्तो फर्कने



Then back to position #1. Lying on your belly  
अनि फेरि शुरूको (घोप्टो) आसनमा फर्कने

3. 30 minutes-2 hours: sitting up

३. ३० मिनेट देखि २ घन्टा: ठाडो बस्ने



Self Positioning Guide. Elmhurst Hospital\_SB  
आफ्नै आसन बदल्ने निर्देशिका (एल्महर्स्ट अस्पताल, अमेरिका)

The awake prone positioning is advised in patients who are alert, able to communicate and has stable hemodynamics. Close monitoring of mental status, oxygen saturation and blood pressure is essential to find out deterioration<sup>8</sup>

<sup>5</sup> Koeckerling D, Barker J, Mudalige NL, *et al*. Awake prone positioning in COVID-19. *Thorax* 2020;**75**:833–834

<sup>6</sup> McNicholas, Bairbre *et al*. "Prone positioning in COVID-19 acute respiratory failure: just do it?." *British journal of anaesthesia* vol. 125,4 (2020): 440-443. doi:10.1016/j.bja.2020.06.003


<sup>7</sup> Ng Z, Tay WC, Ho CHB. Awake prone positioning for non-intubated oxygen dependent COVID-19 pneumonia patients. *Eur Respir J* 2020;56:2001198

<sup>8</sup> Interim Clinical Guidance for Care of Patients with COVID-19 in Healthcare Settings. Nepal Medical Council, October 20202

## Algorithm 6. Treatment for Children with septic shock

### Fluid and Vasoactive-Inotrope Management Algorithm For Children



Surviving Sepsis Campaign



This algorithm, from the Surviving Sepsis Campaign, is based on recently published paediatric sepsis and septic shock guidelines and has been adapted for use in health care systems with and without intensive care (see References and resources).

## Initial Resuscitation Algorithm for Children

Surviving Sepsis Campaign



\*See fluid and vasoactive algorithm. Note: Fluid bolus should be omitted from bundle if a) fluid overload is present or b) it is a low-resource setting without hypotension. Fluid in mL/kg should be dosed as ideal body weight.

\*\*Hydrocortisone may produce benefit or harm.

## Algorithm 7. Delivering increasing oxygen in ADULT

### How to deliver increasing oxygen



Place prongs inside the nostril. Hook tubing behind ears. Flow rates higher than 5 L will dry mucous membranes.

- Start oxygen at 5 L/min
- Use nasal prongs
- Assess response

If increasing respiratory distress or  $SpO_2 < 90\%$ \*



Secure mask firmly on face over nose and mouth. Pull strap over head.

- Use face mask
- Increase oxygen to 6–10 L/min
- Assess response

If increasing respiratory distress or  $SpO_2 < 90\%$ \*



Make sure bag is full to deliver highest oxygen concentration. An empty bag is dangerous.

- Use face mask with reservoir
- Increase oxygen to 10–15 L/min
- Make sure bag inflates
- Call for help from district clinician
- Assess response

If increasing respiratory distress or  $SpO_2 < 90\%$ \*, transfer to a hospital with available invasive mechanical ventilator possible

- Call for help from district clinician for possible tracheal intubation
- Start manual ventilation (bagging) with high-oxygen flow

#### Estimating $FiO_2$ when delivering oxygen

##### Adults

- 2–4 L/min ~  $FiO_2$  0.28–0.36
- 5 L/min ~  $FiO_2$  0.40
- 6–10 L/min ~  $FiO_2$  0.44–0.60
- 10–15 L/min ~  $FiO_2$  0.60–0.95

##### Note:


\* Patients presenting with emergency signs should receive oxygen therapy if  $SpO_2$  is  $< 94\%$ .

##### Emergency signs:

- Obstructed or absent breathing
- Severe respiratory distress
- Central cyanosis
- Signs of shock, defined as cold extremities with capillary refill time  $> 3$  sec and weak and fast pulse
- Coma (or seriously reduced level of consciousness)
- Seizures
- Signs of severe dehydration: lethargy or unconscious, sunken eyes, very slow return after pinching the skin.

# Algorithm 8: Delivering increasing oxygen in CHILDREN

Algorithm 8: Delivering increasing oxygen in CHILDREN



## Footnotes for algorithm boxes 1-6

**a** If altitude is higher than 1000 m, then the correction factor should be calculated as follows:  $\text{PaO}_2/\text{FiO}_2 \times \text{barometric pressure}/760$ .

**b** When  $\text{PaO}_2$  is not available,  $\text{SpO}_2/\text{FiO}_2 \leq 315$  suggests ARDS (including in non-ventilated patients).

**c** Oxygenation Index (OI) is an invasive measurement of the severity of hypoxaemic respiratory failure and may be used to predict outcomes in paediatric patients. It is calculated as follows: percentage of fraction of inhaled oxygen multiplied by the mean airway pressure (in mmHg), divided by the partial pressure of arterial oxygen (in mmHg). Oxygen saturation index (OSI) is a non-invasive measurement and has been shown to be a reliable surrogate marker of OI in children and adults with respiratory failure. OSI replaces  $\text{PaO}_2$  with oxygen saturation as measured by pulse oximetry ( $\text{SpO}_2$ ) in the OI equation.

**d** The SOFA score ranges from 0 to 24 and includes points related to six organ systems: respiratory (hypoxaemia defined by low  $\text{PaO}_2/\text{FiO}_2$ ); coagulation (low platelets); liver (high bilirubin); cardiovascular (hypotension); central nervous system (low level of consciousness defined by Glasgow Coma Scale); and renal (low urine output or high creatinine). Sepsis is defined by an increase in the sepsis-related SOFA score of  $\geq 2$  points. Assume the baseline score is 0 if data are not available (62).

**e** SIRS criteria: abnormal temperature ( $> 38.5^\circ\text{C}$  or  $< 36^\circ\text{C}$ ); tachycardia for age or bradycardia for age if  $< 1$  year; tachypnoea for age or need for mechanical ventilation; abnormal white blood cell count for age or  $> 10\%$  bands.

**Abbreviations:** BP blood pressure; bpm beats per minute; CPAP continuous positive airway pressure;  $\text{FiO}_2$  fraction of inspired oxygen; MAP mean arterial pressure; NIV non-invasive ventilation; OI Oxygenation Index; OSI Oxygenation Index using  $\text{SpO}_2$ ;  $\text{PaO}_2$  partial pressure of oxygen; PEEP positive end-expiratory pressure; SBP systolic blood pressure; SD standard deviation; SIRS systemic inflammatory response syndrome; SOFA sequential organ failure assessment;  $\text{SpO}_2$  oxygen saturation

## Indications of intubation

1. Worsening respiratory distress with SpO<sub>2</sub> < 90% despite oxygen supplementation with non-rebreathing face mask and or failure of HFNO/NIV
2. PaO<sub>2</sub>/FiO<sub>2</sub> <150 mmHg
3. Full airborne precautions need to be taken during bag and mask ventilation and intubation.

## High flow Nasal Oxygen (HFNO) and Non-invasive ventilation (NIV)<sup>9,10</sup>

For adult patients with acute hypoxic respiratory failure despite supplementation of oxygen by non-rebreather mask, and no urgent indication for intubation, high flow nasal oxygen is feasible. Almost half of those who receive it can be successfully weaned without the need for mechanical ventilation. It appears to be safe for health care workers and could well liberate critical ICU resources. If HFNO is not available, non-invasive ventilation can be tried. Awake prone positioning can be considered in alert and hemodynamic patient on NIV or HFNO.

### Precautions:

1. It should not be used in patients who needs urgent intubation such as hypoxaemic respiratory failure and haemodynamic instability, multiorgan failure or abnormal mental status.

---

<sup>9</sup> G.L. Calligaro et al., The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study, *EClinicalMedicine* (2020), <https://doi.org/10.1016/j.eclinm.2020.100570>

<sup>10</sup> Guy, Tiphaine et al. "High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU." *The European respiratory journal*, 2001154. 9 Sep. 2020, doi:10.1183/13993003.01154-2020

2. Patients receiving a trial of HFNO or NIV should be monitored by personnel experienced with HFNO and/or NIV and capable of performing endotracheal intubation in case the patient acutely deteriorates or does not improve after a short trial (about 1 hour). Intubation should not be delayed if the patient acutely deteriorates or does not improve after a short trial. Adult HFNO systems can deliver 60 L/min of gas flow and FiO<sub>2</sub> up to 1.0. Paediatric circuits generally only handle up to 25 L/min, and many children will require an adult circuit to deliver adequate flow.
3. Aerosols generation is a concern and precautions should be taken including putting surgical mask over HFNO.
4. Viral filters or high efficiency particulate air (HEPA) filter should be used in NIV.



## 7.1 CORTICOSTEROID THERAPY AND COVID-19

In patients with severe or critical COVID-19 disease dexamethasone is strongly recommended. Hydrocortisone or prednisolone can be used when dexamethasone is not available. Other indication of corticosteroids is patients requiring supplemental oxygen to meet their desired oxygen level. Continue corticosteroids for up to 10 days unless there is a clear indication to stop early which includes discharge from hospital or a hospital supervised virtual COVID ward.

Systemic corticosteroid therapy of:

- ✓ 6 mg Dexamethasone orally or intravenously daily for 10 days (or until hospital discharge whichever comes earlier) for adult and 150 micrograms/kg (as a base) orally, nasogastrically or intravenously once a day for 10 days (max 6 mg) in children

**OR**

- ✓ 50 mg of Hydrocortisone intravenously every 8 hours for 10 days

**OR**

- ✓ Prednisolone 40 mg once daily for 10 days for adults and 1 mg/kg orally, nasogastrically or intravenously once a day for 10 days (max 40 mg; doses can be rounded as per routine clinical practice)

Do not routinely use corticosteroids to treat COVID-19 in people who do not need supplemental oxygen, unless there is another medical indication to do so.

**Pregnant Women:** WHO recommends antenatal corticosteroid therapy for women at risk of preterm birth from 24 to 34 weeks of gestation when there is no clinical evidence of maternal infection, and adequate childbirth and newborn care is available. However, in cases where the woman presents with mild COVID-19, the

clinical benefits of antenatal corticosteroid might outweigh the risks of potential harm to the mother. In this situation, the balance of benefits and harms for the woman and the preterm newborn should be discussed with the woman to ensure an informed decision. This assessment may vary depending on the woman's clinical condition, her wishes and that of her family, and available health care resources<sup>5</sup>.

## 7.2 Remdesivir

The conditional recommendation against the use of REMDESIVIR for patients with COVID-19 in Therapeutics and COVID-19: living guideline - World Health Organization is based on the evidence of possibly no effect on mortality, need for mechanical ventilation, recovery from symptoms and other patient-important outcomes, though of albeit of low certainty.

NICE guidelines put conditional recommendation for COVID-19 pneumonia in adults, and young people 12 years and over weighing 40 kg or more, who are in hospital and on supplemental oxygen but not on invasive mechanical ventilation for 5 days with a dose of 200 mg on day 1 followed by 100 mg daily for 4 days.

## 7.3 Tocilizumab

Tocilizumab is recommended (strong recommendation) to adults in hospital with COVID-19 if all of the following apply:

- they are having or have completed a course of corticosteroids such as dexamethasone, unless they cannot have corticosteroids
- they have not had another interleukin-6 inhibitor during this admission
- there is no evidence of a bacterial or viral infection (other than SARS-CoV-2) that might be worsened by tocilizumab.
- And they either:

---

<sup>11</sup> Corticosteroids for COVID-19: Living guidance: 2 September 2020: WHO

<sup>12</sup> Therapeutics and COVID-19: living guideline - World Health Organization (WHO), 31 March 2021

<sup>13</sup> COVID-19 rapid guideline: managing COVID-19 NICE guideline Published: 23 March 2021 [www.nice.org.uk/guidance/ng191](http://www.nice.org.uk/guidance/ng191)

- need supplemental oxygen and have a CRP level of 75 mg/L or more, or
- are within 48 hours of starting high-flow nasal oxygen, continuous positive airway pressure, non-invasive ventilation or invasive mechanical ventilation

Common side effects are URT infections, nasopharyngitis, headache, hypertension, increased alanine aminotransferase (adverse effects are ALT), injection site reactions)

Dosage: A single dose of 8 mg/Kg by intravenous infusion (total dose not exceeding 800 mg)

### **Convalescent plasma therapy:**

Only a few clinical trials of convalescent plasma have produced results, and the evidence, at least so far, has not been convincing enough to endorse it beyond use as an experimental therapy.

WHO: There are a number of side effects ranging from mild fevers to severe lung injuries or circulatory overload.

### **Not recommended agents**

WHO recommends AGAINST administering HYDROXYCHLOROQUINE or CHLOROQUINE OR IVERMECTIN or LOPINAVIR/RITONAVIR for treatment of COVID-19 to patients with any disease severity and any duration of symptoms.

## 8. TREATMENT OF OTHER ACUTE AND CHRONIC INFECTIONS IN PATIENTS WITH COVID-19

- 8.1 **Use of antimicrobials:** The prevalence of acute co-infections or secondary infections coinciding with COVID-19 has been not adequately described but appears to be low and will be based on local factors and endemic or other emerging infections.

The following recommendations for patients with:

- ✖ suspected or confirmed mild COVID-19,
  - o against the use of antibiotic therapy or prophylaxis
- ! suspected or confirmed moderate COVID-19,
  - o antibiotics should not be prescribed unless there is clinical suspicion of a bacterial infection.

Suspected or confirmed severe COVID-19

- ✓ Administer empiric antimicrobials to treat all likely pathogens, based on clinical judgment, patient host factors and local epidemiology, and this should be done as soon as possible (within 1 hour of initial assessment if possible), ideally with blood cultures obtained first. Antimicrobial therapy should be assessed daily for de-escalation and reviewed to treat based on microbiology results.
  - o **ADULT:** Ceftriaxone 1-2g, once daily PLUS Azithromycin 500mg, once daily OR Ampicillin 2g IV, 4 times day PLUS Azithromycin 500mg, once daily
  - o **CHILD:** Ampicillin 50mg/kg or Benzylpenicillin 50,000U/kg IM or IV every 6 hours for 5 days PLUS Gentamycin 7.5 mg/kg IM or IV once daily for at least 5 days
- ✓ If bacterial pneumonia or sepsis is suspected use Ceftriaxone or Amoxicillin-Clavulanic Acid
  - o Add Azithromycin for atypical coverage of pneumonia substitute with Doxycycline if allergic to macrolides

- 8.2 **Chronic infections:** It is currently unknown whether immunosuppression caused by chronic co-infections such as HIV put persons at greater risk for severe COVID-19 disease. However, people living with HIV with advanced disease have an increased risk of opportunistic infections (notably TB) and related complications in general. Facility-based HIV testing services should be continued and those newly diagnosed should start antiretroviral therapy as soon as possible. For people living with HIV already on treatment, continuity of antiretroviral therapy and prophylaxis for co-infections is essential, with multi-month prescribing.
- 8.3 **Endemic diseases** (co-morbidities) e.g. malaria, dengue, typhoid etc. should be treated in accordance with the appropriate treatment protocols at the facility level. Many of the endemic diseases have similar clinical presentation as COVID-19 disease, use the differential diagnostic matrix (Annex 4) to facilitate diagnosis.

## 9 USE OF OSELTAMIVIR

Oseltamivir is currently not proven to be effective for COVID-19. Oseltamivir can be used when influenza is suspected or known to be circulating. If testing for influenza is not possible, empirical treatment is indicated.

Oseltamivir has not been evaluated in severely ill patients, pregnancy, or pediatric populations. Oseltamivir should be used with caution.

## 10 USE OF VASOPRESSORS

In adults, administer vasopressors when shock persists during or after fluid resuscitation. The initial blood pressure target is MAP  $\geq 65$  mmHg in adults and improvement of markers of perfusion. Norepinephrine is considered the first-line treatment in adult patients; epinephrine or vasopressin can be added to achieve the MAP target. Because of the risk of tachyarrhythmia, reserve dopamine for selected patients with low risk of tachyarrhythmia or those with bradycardia. For children, refer to algorithm 6. Vasopressors (i.e. norepinephrine, epinephrine, vasopressin and dopamine) are most safely given through a central venous catheter at a strictly controlled rate, but it is also possible to safely administer them via peripheral vein and intraosseous,

## 11 USE OF INOTROPES

Side-effects of inotropes, such as dobutamine, include tachyarrhythmias and hypotension due to peripheral vasodilation. Thus, in septic shock, inotropes should be used in combination with vasopressors to maintain MAP at goal in adults, and children with low systemic vascular resistance.

## 12 NON-COMMUNICABLE DISEASES (NCD) and COVID-19

When caring for patients with suspected and confirmed COVID-19 with underlying NCDs, we may need to continue or modify previous medical therapy according to the patient's clinical condition.

- 12.1 Antihypertensive patients: antihypertensive drugs should not routinely be stopped in patients with COVID-19, but therapy may need to be adjusted based on general considerations of patients with acute illness, with reference to maintaining normal blood pressure and renal function

- 12.2 Asthmatic patients: Respiratory viral infections, such as COVID-19, can trigger and worsen asthma symptoms. However, at present, there is no evidence suggesting that people with asthma are any more likely to contract COVID-19 than anyone else. Continue to administer regular treatment for asthmatic patients, monitor peak flow and respiratory function tests according to facility protocol.
- 12.3 Diabetic patients: are at a higher risk of severe COVID - 19 disease and associated mortality due to COVID-19. However, controlled diabetic patients have more favorable outcomes than non-controlled. Monitor blood sugar levels regularly and manage according to facility protocol.
- 12.4 Patients with myocarditis: refer to cardiologist consultant for appropriate management.

## 13 PREVENTION OF COMPLICATIONS IN HOSPITALIZED AND CRITICALLY ILL PATIENTS WITH COVID-19

### 13.1 Thromboembolism

Adults and adolescents:

- ✓ Use low molecular weight heparin, if contraindicated use mechanical prophylaxis including intermittent pneumatic devices. Enoxaparin 40 mg by subcutaneous injection every 24h or UFH subcutaneously 12 hourly.
- ✓ Monitor patients for signs and symptoms suggestive of thromboembolism.
- ✓ If thromboembolism is suspected proceed immediately to the area/center with diagnostic and management facility.

## 13.2 Other complications

These interventions are based on surviving sepsis or other guidelines and are based on limited feasible recommendations based on high-quality evidence.

<b>Table 3.</b> Anticipated outcome*	Interventions
Reduce days if invasive mechanical ventilation	<ul style="list-style-type: none"> <li>• Use weaning protocols that include daily assessment for readiness to breathe spontaneously</li> <li>• Minimize continuous or intermittent sedation, targeting specific titration endpoints (light sedation unless contraindicated) or with daily interruption of continuous sedative infusions</li> <li>• Early mobilization</li> <li>• Implementation of the above as a bundle of care (may also reduce delirium); such as the Awakening and Breathing Coordination, Delirium assessment/management, and Early mobility (ABCDE)</li> </ul>
Reduce incidence of ventilator-associated pneumonia	<ul style="list-style-type: none"> <li>• Oral intubation is preferable to nasal intubation in adolescents and adults.</li> <li>• Keep patient in semi-recumbent position (head of bed elevation 30–45°)</li> <li>• Use a closed suctioning system; periodically drain and discard condensate in tubing</li> <li>• Use a new ventilator circuit for each patient; once patient is ventilated, change circuit if it is soiled or damaged, but not routinely</li> <li>• Change heat moisture exchanger when it malfunctions, when soiled, or every 5–7 days</li> </ul>
Reduce incidence of catheter-related bloodstream infection	<ul style="list-style-type: none"> <li>• Use a checklist with completion verified by a real-time observer as reminder of each step needed for sterile insertion and as a daily reminder to remove catheter if no longer needed</li> </ul>
Reduce incidence of pressure ulcers	<ul style="list-style-type: none"> <li>• Turn patient every 2 hours</li> </ul>



Reduce incidence of stress ulcers and gastrointestinal (GI) bleeding	<ul style="list-style-type: none"> <li>● Give early enteral nutrition (within 24–48 hours of admission)</li> <li>● Administer histamine-2 receptor blockers or proton-pump inhibitors in patients with risk factors for GI bleeding. Risk factors for GI bleeding include mechanical ventilation for <math>\geq 48</math> hours, coagulopathy, renal replacement therapy, liver disease, multiple comorbidities, and higher organ failure score</li> </ul>
<p>Reduce the development of antimicrobial resistance</p> <p>Reduce the development of adverse drug effects</p> <p>Promote appropriate antimicrobial prescribing and use during the COVID19 pandemic</p>	<ul style="list-style-type: none"> <li>● Utilize de-escalation protocols as soon as patient is clinically stable and there is no evidence of bacterial infection</li> <li>● Expose patient to empiric antimicrobial therapy for the shortest time possible, to prevent nephrotoxicity, cardiac and other side-effects from unnecessary antimicrobial use</li> <li>● <b>Do not prescribe antibiotics to suspected or confirmed COVID-19 patients with low suspicion of a bacterial infection</b>, to avoid more short-term side effects of antibiotics in patients and negative long-term consequences of increased antimicrobial resistance</li> </ul>

*\*Refer to: Clinical Management of COVID-19 Interim Guidance; May 2020; Page 27: WHO*

### 13.3 Nutrition

- ✓ Start enteral feeding early.
- ✓ Nasogastric or orogastric tube feeding in intubated patients
- ✓ Consider parenteral nutrition if enteral feeding is not tolerated despite prokinetics use or if enteral feeding is contraindicated.

## 14 MANAGEMENT OF PREGNANT AND LACTATING WOMEN AND COVID-19<sup>14-15</sup>

There is limited data on the clinical presentation and maternal and perinatal outcomes of COVID-19 disease during or after pregnancy. Existing evidence has not identified major risks or complications in babies born to mothers with COVID-19. However, COVID-19 Pregnant and post-partum women: with pre-existing or pregnancy related co-morbidities (e.g. pregnancy induced hypertension, gestational diabetes), should also be considered for close monitoring.

All pregnant women with history of contact with a person with confirmed COVID-19 be carefully monitored considering asymptomatic transmission of COVID-19. Pregnant or recently pregnant women with suspected or confirmed mild COVID-19 may not require acute care in hospital, unless there is concern for rapid deterioration or an inability to promptly return to hospital; but isolation to contain virus transmission is recommended, and can be done at a health facility, community facility or at home, according to established COVID-19 care pathways but women with moderate or severe COVID-19 require acute care in the hospital, as there is concern for rapid deterioration.

WHO recommends that induction of labour and caesarian section should only be undertaken when medically justified and based on maternal and fetal conditions. COVID-19 status alone is not an indication for caesarian section.

- ✓ Delayed umbilical cord clamping (not earlier than 1 minute) is recommended for improved maternal and infant health and nutritional outcomes. The risk of transmission of COVID-19 through blood is likely to be minimal
- ✓ Mothers with suspected or confirmed COVID-19 should be encouraged to initiate or continue to breastfeed. Mothers should be counselled that the benefits of breastfeeding substantially outweigh the potential risk for transmission
- ✓ Symptomatic mothers who are breastfeeding or practicing skin-to-skin contact or kangaroo mother care should practice respiratory hygiene (wear a cloth mask), including during feeding perform hand hygiene before and after contact with

the child, and routinely clean and disinfect surfaces which the symptomatic mother has been in contact with.

- ✓ See algorithms 1, 2, 3, 4, 5, 7 for management of pregnant women according to disease severity.

## 15 MANAGEMENT OF NEUROLOGICAL AND MENTAL MANIFESTATIONS ASSOCIATED WITH COVID-19<sup>1</sup>

In patients with COVID-19, measures to prevent delirium, an acute neuropsychiatric emergency, should be implemented; and patients be evaluated using standardized protocols, for the development of delirium. If detected, then immediate evaluation by a clinician is recommended to address any underlying cause of delirium and treat appropriately.

- ✓ Manage any underlying cause of delirium by monitoring oxygenation and fluid status, correcting metabolic or endocrine abnormalities, addressing co-infections, minimizing the use of medications that may cause or worsen delirium, treating withdrawal from substances, understanding and minimizing the effects of any harmful drug-drug interactions and maintaining normal sleep cycle as much as possible.
- ✓ In patients receiving invasive ventilation, minimize continuous or intermittent sedation, targeting specific titration endpoints (light sedation unless contraindicated) or with daily interruption of continuous sedative infusions, to reduce delirium.
- ✓ In patients experiencing agitation (defined as marked restlessness or excessive motor activity, often accompanied by anxiety), use calming communication strategies and attempt to reorient the person. Acute pain due to physical illness or air hunger should be considered as triggers for agitation and need to be addressed immediately. If the person continues to be agitated despite the strategies

---

<sup>14</sup> WHO recommendations for induction of labour. Geneva: World Health Organization; 2011 ([https://www.who.int/reproductivehealth/publications/maternal\\_perinatal\\_health/9789241501156/en/](https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241501156/en/), accessed 14 May 2020).

<sup>15</sup> <https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/covid-19-and-breastfeeding.html>

described above and is experiencing severe distress, it may be necessary to use psychotropic medications.

- ✓ Provide basic mental health and psychosocial support (MHPSS) for all persons with suspected or confirmed COVID-19.
- ✓ Prompt identification and assessment for anxiety and depressive symptoms in the context of COVID-19 is important, for the management of new anxiety and depressive symptoms.
- ✓ If a person's anxiety or depressive symptoms persist beyond recovery from COVID19 and/or discharge from the hospital, then an underlying anxiety or depressive disorder may be suspected, and a mental health professional should be consulted, and these conditions should be managed appropriately.

## 16. REHABILITATION FOR PATIENTS WITH COVID-19<sup>1</sup>

Patients with COVID-19, regardless of the disease severity, might present with persistent symptoms and a functional decline which may not be obviously apparent. Few common symptoms are new illness-related fatigue, breathlessness, PTSD symptoms, pain, voice change, cough, dysphagia, anxiety, depression, and problems with concentration, memory and continence are increasingly reported in patients who have recovered from acute COVID-19 even up to months. Prior to hospital discharge, COVID-19 patients should be screened for rehabilitation needs in order to facilitate onward referral. A multidisciplinary approach is recommended for better outcome. Nevertheless, the following interventions are useful.

- Patients with COVID-19, should be provided with education and support for the self-management of breathlessness and resumption of activities.
- All rehabilitating patients should be educated about resuming everyday activities conservatively at an appropriate pace that is safe and manageable for energy levels within the limits of current symptoms and should not be pushed for post-

exertional fatigue. A gradual increase in exercise should be based on symptoms.

- ✓ For patients having difficulties with memory, concentration and problem solving, education should be provided, and advice on strategies to help establish expectations (including from family members) and to alleviate stress and anxiety.
- ✓ For patients with anxiety, depression and PTSD, basic mental health and psychosocial support by appropriately trained health or non-health workers should be provided.

## ANNEX 1: APPROPRIATE USE OF PPE ACCORDING TO TASK

### Guidelines for use of personal protective equipment

(Developed by the Expert Team of NMC and Government of Nepal with reference from WHO, published on March 26, 2020)

**A. For Aerosol Generating procedures:** Dental procedures, bronchoscopy, Upper GI Endoscopy, ENT procedures, Nebulization, Intubation of a patient, CPR, Non-invasive ventilation, endotracheal suctioning, when obtaining nasopharyngeal or oropharyngeal swab, etc. **in Covid-19 suspected or confirmed cases health personnel need to use the following protective equipment: Category I PPE:**

- a. N-95 mask
- b. Goggles or visor
- c. Gloves (loose gloves acceptable)
- d. Water resistant OR standard disposable gowns
- e. Cap: Regular disposable

**B. For Non aerosol generating covid-19 suspected or confirmed patients: Health personnel need to use the following protective equipment: Category II PPE:**

- a. Surgical mask (seal the top edge with tape)\*
- b. Goggles or visor
- c. Gloves (loose gloves acceptable)
- d. Water resistant or standard disposable gowns
- e. Cap: Regular disposable

**C. For Physician/Staff running the fever/screening clinics the following PPE is recommended: Category II PPE**

- a. Surgical mask, (seal the top edge with a tape)\*
- b. Goggles or visor
- c. Water resistant or standard disposable gowns
- d. Regular disposable Cap
- e. Gloves (loose gloves acceptable)

**D. For escorts or drivers, the following PPE is recommended: Category III PPE:**

- a. Surgical masks
- b. Gloves
- c. If physical contact is expected, depending on circumstances, a gown PLUS goggles or face shield are also recommended, otherwise need to maintain minimum 2-meter distance from the

patient.

d. The patient should be given surgical mask and instructed to perform hand-hygiene.

**E. For Laboratory staff: category II or III PPE; depending upon the chance of splash:**

a. surgical mask

b. Gown

c. Loose Gloves

d. Eye protection (if risk of splash)

**F. For all staff, including health care workers** involved in any activity that does not involve contact with

COVID-19 patients and working in other areas of patient transit (e.g. wards, corridors). **No PPE**

**required.**

**For Everyone:**

o *Maintain 3-6 feet distance while visiting patients, if no need to touch the patient.*

o *Mandatory hand-hygiene after each use of PPE and between patients.*

*Mandatory surface cleaning of bed or furniture with 0.5% Chlorine disinfectant (Virex\* or similar) between each patient in OPD or in an inpatient setting.*

**\*Use N-95 masks if close contact with COVID-19 suspect or confirmed case expected.**

### **SCREENING QUESTIONNAIRE :**

All individuals presenting to the OPD or ER entrance should be screened with the following questions:

**a. Symptoms:** Do you have any of the following symptoms?

- Cough? Fever? Shortness of breath? (common)
- Sore throat, headache or body ache, new loss of smell, or taste? (less common)

**b. Travel history or contact with traveler:**

#### **Have you**

- Recently returned from travel in, or been living in, an affected area in the past 2 weeks?
- Been in close contact in the past 2 weeks with someone returning from travel in an affected area?

#### **c. Exposures:**

Did you have any exposures to any of the following?

- Close contact with anyone with fever or respiratory illness of unknown cause
- Known or suspected COVID-positive contact



## ANNEX 3. EDUCATION FOR PATIENTS; HOW TO PERFORM HAND HYGIENE, COUGH ETIQUETTE, WEAR A MASK PROPERLY

# How to Handwash?

WASH HANDS WHEN VISIBLY SOILED! OTHERWISE, USE HANDRUB



**Duration of the entire procedure: 40-60 seconds**

**0**



Wet hands with water;

**1**




Apply enough soap to cover all hand surfaces;

**2**



Rub hands palm to palm;

**3**



Right palm over left dorsum with interlaced fingers and vice versa;

**4**



Palm to palm with fingers interlaced;

**5**



Backs of fingers to opposing palms with fingers interlocked;

**6**



Rotational rubbing of left thumb clasped in right palm and vice versa;

**7**



Rotational rubbing, backwards and forwards with clasped fingers of right hand in left palm and vice versa;

**8**



Rinse hands with water;

**9**




Dry hands thoroughly with a single use towel;

**10**



Use towel to turn off faucet;


**11**



Your hands are now safe.


# How to Handrub?

**RUB HANDS FOR HAND HYGIENE! WASH HANDS WHEN VISIBLY SOILED**


 **Duration of the entire procedure: 20-30 seconds**



Apply a palmful of the product in a cupped hand, covering all surfaces;



Rub hands palm to palm;



Right palm over left dorsum with interlaced fingers and vice versa;




Palm to palm with fingers interlaced;




Backs of fingers to opposing palms with fingers interlocked;



Rotational rubbing of left thumb clasped in right palm and vice versa;




Rotational rubbing, backwards and forwards with clasped fingers of right hand in left palm and vice versa;



Once dry, your hands are safe.

## Protect others from getting sick

When coughing and sneezing  
**cover mouth and nose** with  
flexed elbow or tissue



**Throw tissue into closed bin**  
**immediately after use**

**Clean hands** with alcohol-based  
hand rub or soap and water  
after coughing or sneezing and  
when caring for the sick



World Health  
Organization

# HOW TO WEAR A MEDICAL MASK SAFELY

[who.int/epi-win](https://who.int/epi-win)

## Do's →



Find the top side, where the metal piece or stiff edge is



Ensure the colored-side faces outwards



Place the metal piece or stiff edge over your nose



Cover your mouth, nose, and chin



Adjust the mask to your face without leaving gaps on the sides



Avoid touching the mask



Remove the mask from behind the ears or head



Keep the mask away from you and surfaces while removing it



Discard the mask immediately after use preferably into a closed bin



Wash your hands after discarding the mask

## Don'ts →



Do not Use a ripped or damp mask



Do not wear the mask only over mouth or nose



Do not wear a loose mask



Do not touch the front of the mask



Do not remove the mask to talk to someone or do other things that would require touching the mask



Do not leave your used mask within the reach of others



Do not re-use the mask

**Remember that masks alone cannot protect you from COVID-19. Maintain at least 1 metre distance from others and wash your hands frequently and thoroughly, even while wearing a mask.**

EPI·WIN



World Health Organization

## ANNEX 4: DIFFERENTIAL DIAGNOSIS MATRIX

Symptoms	COVID-19	Flu	Common Cold	Malaria	Dengue	Scrub Typhus	Allergies
Fever	Common	Common	Rare	Common	Common	Common often with chills	Rare
Dry Cough	Common	Less Common	Less Common	Rare	Rare	Less Common	Less Common
Tiredness	Common	Common	Less Common	Common	Common	Less Common	Less Common
Shortness of Breath	Less Common	Less Common	Rare	Rare	Less Common	Common	Less Common
Aches and Pains	Less Common	Common	Rare	Less Common	Common	Less Common	Rare
Headache	Less Common	Common	Rare	Common	Common	Common	Less Common
Sore throat	Less Common	Less Common	Common	Rare	Rare	Rare	Rare
Diarrhea	Less Common	Less Common	Rare	Common	Rare	Rare	Rare
Stuffy Nose	Rare	Less Common	Common	Rare	Rare	Rare	Common
Running Nose	Rare	Common	Common	Rare	Less Common	Rare	Common
Sneezing	Rare	Rare	Common	Rare	Rare	Rare	Common
Rash	Less Common	Rare	Rare	Rare	Common, exanthematous rash, petechiae	Common, maculopapular	Common

## ANNEX 5: NATIONAL EARLY WARNING SCORE 2

**The National Early Warning Score (NEWS) 2** is based on a simple aggregate scoring system allocated to following physiological measurements which are routinely recorded in hospitalized patients.

1. Respiration rate
2. Oxygen saturation
3. Systolic blood pressure
4. Pulse rate
5. Level of consciousness or new confusion\*
6. Temperature

\*The patient may respond to questions coherently, but there may be some new-onset confusion, disorientation and/or agitation which score 3 on NEWS system (3 or 4 in GCS).

The use of NEWS 2 will ensure that patients who are deteriorating, or at risk of deteriorating, will have a timely initial assessment by a competent clinical decision maker. NEWS2 should supplement clinical judgement in assessing the patient's condition.

A score is allocated to each parameter as they are measured. The score is then aggregated and frequency of observations and review by appropriate team is decided. If patient is receiving oxygen supplementation, 2 points will be added to score.

In the context of **COVID-19 infection**, oxygen requirement of a patient might increase rapidly but this may not result in additional significant increase (>3) in NEWS 2 score. It is recommended that in patients with COVID-19, all staffs should be aware that any increase in oxygen requirement should trigger an escalation call to a competent clinical decision maker along with increase in observations to at least hourly until a clinical review.

Chart 1: The NEWS scoring system

Physiological parameter	3	2	1	Score 0	1	2	3
Respiration rate (per minute)	≤8		9–11	12–20		21–24	≥25
SpO <sub>2</sub> Scale 1 (%)	≤91	92–93	94–95	≥96			
SpO <sub>2</sub> Scale 2 (%)	≤83	84–85	86–87	88–92 ≥93 on air	93–94 on oxygen	95–96 on oxygen	≥97 on oxygen
Air or oxygen?		Oxygen		Air			
Systolic blood pressure (mmHg)	≤90	91–100	101–110	111–219			≥220
Pulse (per minute)	≤40		41–50	51–90	91–110	111–130	≥131
Consciousness				Alert			CVPU
Temperature (°C)	≤35.0		35.1–36.0	36.1–38.0	38.1–39.0	≥39.1	

Chart 2: NEWS thresholds and triggers

NEW score	Clinical risk	Response
Aggregate score 0–4	Low	Ward-based response
Red score Score of 3 in any individual parameter	Low–medium	Urgent ward-based response*
Aggregate score 5–6	Medium	Key threshold for urgent response*
Aggregate score 7 or more	High	Urgent or emergency response**

\* Response by a clinician or team with competence in the assessment and treatment of acutely ill patients and in recognising when the escalation of care to a critical care team is appropriate.

\*\*The response team must also include staff with critical care skills, including airway management.

# Chart 3: NEWS observation chart

NEWS key		FULL NAME		
1	2	3		
DATE OF BIRTH		DATE OF ADMISSION		
DATE		DATE		
TIME		TIME		
<b>A+B</b> Respirations Breaths/min	≥25		3	≥25
	21-24		2	21-24
	18-20			18-20
	15-17			15-17
	12-14			12-14
	9-11		1	9-11
	≤8		3	≤8
<b>A+B</b> SpO <sub>2</sub> Scale 1 Oxygen Saturation (%)	≥96		1	≥96
	94-95		2	94-95
	92-93		2	92-93
	≤91		3	≤91
<b>SpO<sub>2</sub> Scale 2</b> Oxygen Saturation (%) <small>Use Scale 2 if target range is 92-95% or in hypercapnic respiratory failure</small> <small>ONLY use Scale 2 under the direction of a qualified clinician</small>	≥97 on O <sub>2</sub>		3	≥97 on O <sub>2</sub>
	95-96 on O <sub>2</sub>		2	95-96 on O <sub>2</sub>
	93-94 on O <sub>2</sub>		1	93-94 on O <sub>2</sub>
	≥93 on air			≥93 on air
	88-92			88-92
	86-87		1	86-87
	84-85		2	84-85
	≤83%		3	≤83%
Air or oxygen?	A= Air			A= Air
	O <sub>2</sub> L/min		2	O <sub>2</sub> L/min
Device				Device
<b>C</b> Blood pressure <small>mmHg</small> <small>Score 4 uses systolic (b) only</small>	≥220		3	≥220
	201-219			201-219
	181-200			181-200
	161-180			161-180
	141-160			141-160
	121-140			121-140
	111-120			111-120
	101-110		1	101-110
	91-100		2	91-100
	81-90			81-90
	71-80		3	71-80
	61-70			61-70
	51-60			51-60
≤50			≤50	
<b>C</b> Pulse Beats/min	≥131		3	≥131
	121-130		2	121-130
	111-120			111-120
	101-110		1	101-110
	91-100			91-100
	81-90			81-90
	71-80			71-80
	61-70			61-70
	51-60		1	51-60
	41-50			41-50
	31-40		3	31-40
	≤30			≤30
	<b>D</b> Consciousness <small>Score for level of confusion into score (if direct)</small>	Alert		
Confusion				Confusion
V			3	V
P				P
U				U
<b>E</b> Temperature °C	≥39.1		2	≥39.1
	38.1-39.0		1	38.1-39.0
	37.1-38.0			37.1-38.0
	36.1-37.0			36.1-37.0
	35.1-36.0		1	35.1-36.0
	≤35.0		3	≤35.0
NEWS TOTAL		TOTAL		
Monitoring Frequency		Monitoring		
Escalation of care Y/N		Escalation		
Initials		Initials		



Chart 4: Clinical response to the NEWS trigger thresholds

NEW score	Frequency of monitoring	Clinical response
0	Minimum 12 hourly	<ul style="list-style-type: none"> <li>Continue routine NEWS monitoring</li> </ul>
Total 1–4	Minimum 4–6 hourly	<ul style="list-style-type: none"> <li>Inform registered nurse, who must assess the patient</li> <li>Registered nurse decides whether increased frequency of monitoring and/or escalation of care is required</li> </ul>
3 in single parameter	Minimum 1 hourly	<ul style="list-style-type: none"> <li>Registered nurse to inform medical team caring for the patient, who will review and decide whether escalation of care is necessary</li> </ul>
Total 5 or more Urgent response threshold	Minimum 1 hourly	<ul style="list-style-type: none"> <li>Registered nurse to immediately inform the medical team caring for the patient</li> <li>Registered nurse to request urgent assessment by a clinician or team with core competencies in the care of acutely ill patients</li> <li>Provide clinical care in an environment with monitoring facilities</li> </ul>
Total 7 or more Emergency response threshold	Continuous monitoring of vital signs	<ul style="list-style-type: none"> <li>Registered nurse to immediately inform the medical team caring for the patient – this should be at least at specialist registrar level</li> <li>Emergency assessment by a team with critical care competencies, including practitioner(s) with advanced airway management skills</li> <li>Consider transfer of care to a level 2 or 3 clinical care facility, ie higher-dependency unit or ICU</li> <li>Clinical care in an environment with monitoring facilities</li> </ul>

Downloaded from rcplondon.ac.uk.

## ANNEX 6: MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN AND ADOLESCENTS

### WITH COVID-19<sup>16,17</sup>

Multisystem Inflammatory syndrome in children (MIS-C) is a new potentially lethal disease temporally associated with COVID-19 disease. WHO has developed a preliminary case definition.

Children and adolescents 0–19 years of age with fever <sup>≥</sup> 3 days **AND** two of the following:

- a. Rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands or feet)
- b. Hypotension or shock.
- c. Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated Troponin/NT-proBNP),
- d. Evidence of coagulopathy (by PT, PTT, elevated d-Dimers).
- e. Acute gastrointestinal problems (diarrhoea, vomiting, or abdominal pain).

### **AND**

Elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin.

### **AND**

No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes.

### **AND**

Evidence of COVID-19 (RT-PCR, antigen test or serology positive), or likely contact with patients with COVID-19.

The common clinical symptoms at presentation are fever (100%), abdominal pain or diarrhea (73%), and vomiting (68%). Signs and

symptoms of MIS-C typically appears after three to four weeks after COVID-19 infection and may progress rapidly to shock and cardiorespiratory failure in many cases. Various immunomodulatory treatments (intravenous immunoglobulin, steroids) have been used. Patients may need mechanical ventilation apart from supportive therapy. Early recognition and referral to a tertiary care center is the key for improving survival.

---

<sup>16</sup> Ahmed M, Advani S, Moreira A et al. Multisystem inflammatory syndrome in children: A systematic review. *E Clinical Medicine* 26 (2020) 100527. <https://doi.org/10.1016/j.eclinm.2020.100527>

<sup>17</sup> Multisystem inflammatory syndrome in children and adolescents with COVID-19. *Scientific brief*. 15 May 2020



**COVID-19**  
**RESPONSE**

